BioSyntech to Conduct Substantial Interim Analysis on Half of Enrolled Patients from BST-CarGel® Pivotal Trial

BioSyntech, Inc. today announced that it will conduct an interim analysis of the available clinical data from 40 subjects who have completed their 12 month follow-up in the 80 subject trial for its cartilage repair device, BST-CarGel®.

Minimally Invasive Percutaneous Osteoplasty Treats Metastatic Bone Pain: Presented at SIR

Injections of bone cement to support weakened bones in patients with metastatic bone disease provide immediate and substantial pain relief for patients, a researcher reported here at the Society of Interventional Radiology (SIR) 34th Annual Scientific Meeting.

FDA Classifies Recent Urgent Device Correction on Baxter’s Colleague Infusion Pump as a Class I Recall

Baxter International Inc. announced today that the U.S. Food and Drug Administration has classified Baxter’s January 23, 2009 Urgent Device Correction letter to customers regarding U.S. COLLEAGUE® Volumetric Infusion Pumps as a Class I recall.

St. Jude Medical Announces European CE Mark Approval of Neurostimulation System for Chronic Angina

St. Jude Medical, Inc. today announced European CE Mark approval of its Genesis® neurostimulation system for managing a form of chest pain known as chronic angina pectoris, or chronic angina.

All-Inclusive Solution For Rigid Posterior Fixation Of The Cervico-Thoracic Regions Of The Spine

K2M, Inc., a spinal device company developing innovative solutions for the treatment of complex spinal pathologies, announced the introduction of an all-inclusive solution for rigid posterior fixation of the cervico-thoracic regions of the spine, the CASPIAN™ Spinal System.

FDA Approves SyntheMed’s REPEL-CV® Adhesion Barrier for Use in Pediatric Cardiac Surgery

SyntheMed, Inc., a biomaterials company engaged in the development and commercialization of anti-adhesion products, today announced that the U.S. Food and Drug Administration has approved the Pre-market Approval application for REPEL-CV® Adhesion Barrier for use in pediatric cardiac surgery patients.

Heavy Lifting: Spinal Fractures No Reason To Sacrifice Height, Says Orthopaedic Medical Device Expert

AOI has pioneered a better way to treat VCF. The company’s lead product, Ascendx™, is used to restore height by pushing on the bone walls while simultaneously delivering a medical grade bone cement, uniformly filling the cavity, thereby restoring height and allowing equal forceload distribution to the vertebra.

Surgeons Perform Minimally Invasive Spine Surgery With US Spine’s Lock-Tight™ Device

Spine surgeons at Middlesex Hospital in Middlesex Connecticut have performed a minimally invasive, posterior spinal fixation procedure using the Lock-Tight™ Facet System, a groundbreaking new technology that enables surgeons to fixate the facet joint without needing to perform an open procedure.

Blood Clots After Hip Or Knee Replacement Surgery – NICE Recommends Xarelto® (rivaroxaban) Use In NHS, UK

Bayer Schering Pharma welcome NICE’s Final Appraisal Determination giving a draft recommendation that Xarelto (rivaroxaban), within its marketing authorisation, is recommended as an option for the prevention of venous thromboembolism in adults having elective total hip or elective total knee replacement surgery.

Most read

Latest

^